companies wanted
click here
Site Map
Search Site Content
Join Us
Contact Us
CBA News
User Login
Partner Login
Business Summary
Print Friendly, PDF & Email
Capital Raising

Investment in Indian pharma company

Mandate ID: IN-22-VGA-1-2205-3
Transaction Type:
Capital Raising

Industry: Pharmaceuticals

Sector: Healthcare


Country of Origin: India | India

Target Countries: India

Target Areas: Worldwide

Capital Raising		 > Investment in Indian pharma company

Business Review

The company is an established player in the generic oncology space, in the business for 17+ years. It is into manufacturing and marketing of chemotherapy, haematology, supportive care and NDDS niche products.


Main product offerings - chemotherapy range - Cisplatin, Carboplatin, Oxaliplatin, Doxorubicin, Etoposide, Cyclophosphamide, Ifosfamide,Flurouracil,Vincristine,Vinblastin,Leucovorin,Methotraxate, Paclitaxel, Docetaxel, Gemcitabine, Epirubicin, daunorubicin, Pemetrexid, Fulvestrant, PFS, Caecitabine, Imatinib, Erlotinib, Dasatinb

Financial Information

Capital required: INR on request.


The company started as a drug marketing company and created a pan India presence in that space. Then it ventured into manufacturing and became an established player in the market. Its products are exported to 30 countries under emergency import permits and registration process is underway. The focus now is on creating a niche in NDDS and peptides. Also venturing into Liposomal delivery system and Nanoparticles.

Request More Information